Non-clinical trials (GLP preliminary safety studies) and development of companion diagnostics are also progressing smoothly, and with this investment, the company plans to complete the companion diagnostics and develop its second pipeline in parallel with GLP safety studies and preparations for clinical trials through the manufacture of investigational new drugs.